Feature – Oncology Drug Treatment

Published in:
Volume 7 / Year 2013 / Issue 2

Personalized medicine with tyrosine kinase inhibitors: the erlotinib case

Page: 32-33

Abstract:Large variability in the pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors warrants dose stratification rather than the use of fixed doses in all patients. Large population-based studies are required to… Read More »

Go Back Print
Webdesign by I2CT
css.php